ValuEngine cut shares of TG Therapeutics, Inc. (NASDAQ:TGTX) from a hold rating to a sell rating in a report published on Monday.
Several other research analysts have also issued reports on the company. SunTrust Banks, Inc. restated a buy rating and set a $28.00 target price on shares of TG Therapeutics in a research report on Tuesday, October 3rd. BidaskClub upgraded TG Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 24th. Finally, Zacks Investment Research lowered TG Therapeutics from a hold rating to a sell rating in a research report on Saturday, August 12th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $25.11.
TG Therapeutics (TGTX) traded up 11.667% on Monday, reaching $8.375. The company’s stock had a trading volume of 1,549,713 shares. TG Therapeutics has a one year low of $4.10 and a one year high of $15.35. The company’s market capitalization is $521.85 million. The firm has a 50-day moving average of $11.53 and a 200-day moving average of $11.25.
TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.01. TG Therapeutics had a negative return on equity of 154.02% and a negative net margin of 68,806.59%. The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. Analysts predict that TG Therapeutics will post ($1.84) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://transcriptdaily.com/2017/10/20/tg-therapeutics-inc-tgtx-lowered-to-sell-at-valuengine.html.
Large investors have recently modified their holdings of the stock. Legal & General Group Plc raised its stake in TG Therapeutics by 4.1% in the first quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 384 shares in the last quarter. Hollencrest Securities LLC bought a new position in TG Therapeutics in the second quarter worth approximately $121,000. Bank of America Corp DE raised its stake in TG Therapeutics by 11.0% in the first quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock worth $164,000 after buying an additional 1,395 shares in the last quarter. UBS Group AG raised its stake in TG Therapeutics by 34.4% in the first quarter. UBS Group AG now owns 14,606 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 3,736 shares in the last quarter. Finally, HighTower Advisors LLC bought a new position in TG Therapeutics in the first quarter worth approximately $170,000. 49.86% of the stock is owned by institutional investors.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.